ADPT - Adaptive Biotechnologies Corporation News

Piper Sandler Maintains Overweight on Adaptive Biotechnologies, Raises Price Target to $27.5

Piper Sandler analyst David Westenberg maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Ov

seekingalpha.com

Adaptive Biotechnologies: The MRD Separation Creates A Pure-Play Compounder

Adaptive Biotechnologies (ADPT) is transitioning to a pure-play MRD diagnostics company, with the sp

Adaptive Biotechnologies Corporation (ADPT) Hit a 52 Week High, Can the Run Continue?

Adaptive Biotechnologies (ADPT) is at a 52-week high, but can investors hope for more gains in the f

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $22

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal

TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $28

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and rais

Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and ra

BTIG Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $25

BTIG analyst Mark Massaro maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and raises

seekingalpha.com

Adaptive Biotechnologies Corporation (ADPT) Q2 2026 Earnings Call Transcript

Adaptive Biotechnologies (ADPT) Reports Q2 Earnings: What Key Metrics Have to Say

While the top- and bottom-line numbers for Adaptive Biotechnologies (ADPT) give a sense of how the b

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Co

marketbeat.com

Adaptive Biotechnologies Q2 Earnings Call Highlights

Adaptive Biotechnologies NASDAQ: ADPT reported second-quarter results marked by accelerating growth

UPDATE: Adaptive Biotechnologies Q2 Adj. EPS $(0.10) Beats $(0.13) Estimate, Sales $71.553M Beat $65

Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.10) per share which beat the

Adaptive Biotechnologies Q2 EPS $(0.25) Misses $(0.14) Estimate, Sales $71.553M Beat $65.886M Estima

Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.25) per share which missed t

Adaptive Biotechnologies Reports Second Quarter 2026 Financial Results

SEATTLE, July 29, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (“Adaptive Biotechno

defenseworld.net

Caxton Associates LLP Has $500,000 Stake in Adaptive Biotechnologies Corporation $ADPT

Caxton Associates LLP trimmed its stake in shares of Adaptive Biotechnologies Corporation (NASDAQ: A

defenseworld.net

D.A. Davidson & CO. Sells 60,300 Shares of Adaptive Biotechnologies Corporation $ADPT

D.A. Davidson and CO. reduced its holdings in shares of Adaptive Biotechnologies Corporation (NASDAQ

Adaptive Biotechnologies (ADPT) May Report Negative Earnings: Know the Trend Ahead of Next Week's Re

Adaptive Biotechnologies (ADPT) doesn't possess the right combination of the two key ingredients for

Adaptive Biotechnologies (ADPT) Upgraded to Buy: What Does It Mean for the Stock?

Adaptive Biotechnologies (ADPT) might move higher on growing optimism about its earnings prospects,

defenseworld.net

Amova Asset Management Americas Inc. Sells 352,593 Shares of Adaptive Biotechnologies Corporation $A

Amova Asset Management Americas Inc. lessened its stake in Adaptive Biotechnologies Corporation (NAS

fool.com

An Adaptive Biotechnologies Insider Sold $8.5 Million in Stock After an 85% Run

Approximately 386,000 shares were liquidated for a total transaction value of $8.5 million on July 2

Adaptive Biotechnologies to Report Second Quarter 2026 Financial Results on July 29, 2026

SEATTLE, July 09, 2026 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a co

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Raises Price Target to $20

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal

Guggenheim Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $22

Guggenheim analyst Subbu Nambi maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and ra

KB Home Posts Upbeat Q2 Sales, Joins Inmode, Icon And Other Big Stocks Moving Higher On Wednesday

U.S. stocks rose, with Nasdaq up 50 points. KB Home (NYSE: KBH) reported strong Q2 results, shares j

Adaptive Biotechnologies Business Separation May Unlock Greater Value

Adaptive Biotechnologies Corporation (NASDAQ:ADPT ) on Monday announced plans to separate its Minima

Adaptive Biotechnologies Business Separation May Unlock Greater Value

William Blair says Adaptive's Immune Medicine separation could sharpen the MRD story, improve fl

BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target

BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and mainta

Adaptive Biotechnologies Prices $300M Upsized Convertible Notes Offering (Up From $250M)

Adaptive Biotechnologies Corporation ("Adaptive Biotechnologies") (NASDAQ:ADPT) today announ

Adaptive Biotechnologies Corporation Prices Upsized $300 Million Convertible Senior Notes Offering

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexib

Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) shares are trading higher during Tuesday's sessio

Adaptive Biotechnologies Stock Rises On Plan To Split MRD, Immune Medicine Businesses

Adaptive Biotechnologies plans to separate its businesses as clonoSEQ profitability and revenue grow

Stock Market Today: S&P 500, Nasdaq Futures Fall, Dow Gains Amid US-Iran Deal— SpaceX, Dave And Bust

(Editor’s note: The lede, headline, futures and economic data were updated.) U.S. stock futures w

Dave and Buster's Reports Downbeat Q1 Earnings, Joins Alvotech And Other Big Stocks Moving Lower In

US stock futures up 0.1%, Dave and Buster's (PLAY) down 13.4% pre-market due to lower earnings;

Why High Tide Shares Are Trading Higher By Around 19%; Here Are 20 Stocks Moving Premarket

HITI rose sharply in pre-market trading on strong Q2 results and continued to rise after market open

John Wiley & Sons, Dave and Buster's Entertainment And 3 Stocks To Watch Heading Into Tuesday

Stock futures lower, Wiley & Sons and Vince Holding expected to report earnings, Dave & Bust

reuters.com

Adaptive Biotechnologies plans separation of immune medicine platform

Adaptive Biotechnologies said on Monday it planned to separate its immune medicine business from it

Adaptive Biotechnologies Plans Separation Of MRD And Immune Medicine Businesses, Targets Preferred P

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial-stage biotechnology company focused

Adaptive Biotechnologies Launches $250M Convertible Senior Notes Offering Due 2031 To Repay OrbiMed

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexib

Adaptive Biotechnologies Announces Plan to Separate Its MRD and Immune Medicine Businesses

MRD has scaled into a profitable, category-leading MRD diagnostics business, while Immune Medicine h

Adaptive Biotechnologies Corporation Announces Proposed Convertible Senior Notes Offering

Proceeds expected to be deployed to repay the OrbiMed Purchase Agreement to enhance financial flexib

Adaptive Biotechnologies Says NGS-Based ClonoSEQ Test For Measurable Residual Disease Assessment Wil

Adaptive Biotechnologies Corporation (NASDAQ:ADPT), a commercial stage biotechnology company that ai

Morgan Stanley Maintains Equal-Weight on Adaptive Biotechnologies, Lowers Price Target to $18

Morgan Stanley analyst Tejas Savant maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Equal

JP Morgan Maintains Overweight on Adaptive Biotechnologies, Lowers Price Target to $19

JP Morgan analyst Sebastian Sandler maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Overw

TD Cowen Maintains Buy on Adaptive Biotechnologies, Raises Price Target to $21

TD Cowen analyst Dan Brennan maintains Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and rais

Guggenheim Reiterates Buy on Adaptive Biotechnologies, Maintains $21 Price Target

Guggenheim analyst Subbu Nambi reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and m

BTIG Reiterates Buy on Adaptive Biotechnologies, Maintains $22 Price Target

BTIG analyst Mark Massaro reiterates Adaptive Biotechnologies (NASDAQ:ADPT) with a Buy and mainta

Transcript: Adaptive Biotechnologies Q1 2026 Earnings Conference Call

Adaptive Biotechnologies Q1 EPS $(0.13) Beats $(0.17) Estimate, Sales $70.874M Beat $60.850M Estimat

Adaptive Biotechnologies (NASDAQ:ADPT) reported quarterly losses of $(0.13) per share which beat the

Earnings Scheduled For May 5, 2026